Study wrapper · #948
Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
Alavi SE, Boshrouyeh R, Raza A, et al. European journal of medicinal chemistry. 2026.
DOI: 10.1016/j.ejmech.2026.118587PubMed: 41547240
Editor's note
A narrative overview of the mechanisms and clinical progress of multi-target incretin agonists. It covers tirzepatide and retatrutide as leading examples but breaks no new ground, noting open questions on safety, access, and long-term use. Suitable as background reading rather than primary evidence.
Plain-language abstract
A review summarizing how dual and triple incretin agonists such as tirzepatide and retatrutide are being studied for type 2 diabetes, obesity, and fatty liver disease.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026